Safety and efficacy in actual clinical practice of once-weekly subcutaneous teriparatide for osteoporosis patients with a high fracture risk
Osteoporosis and Sarcopenia
;
: 44-50, 2019.
Article
in English
| WPRIM
| ID: wpr-760730
ABSTRACT
OBJECTIVES:
To reassess the safety and efficacy of once-weekly teriparatide 56.5 mg in osteoporosis patients with a high fracture risk.METHODS:
This postmarketing observational study was conducted at 72 weeks according to the package insert. Of the 3573 Japanese osteoporosis patients in the safety analysis set, 91.80% were women, the mean age was 78.1 years, and 69.89% had a history of prevalent fragility fractures, indicating that a high proportion of patients at high risk of fracture were enrolled.RESULTS:
Persistence with weekly teriparatide treatment was 59.36%, and 38.95% at 24 and 72 weeks, respectively. Adverse drug reactions (ADRs) were reported in 898 patients (25.13%), and serious ADRs were reported in 26 patients (0.73%). The most frequent ADRs were nausea, vomiting, and headache. The cumulative incidence of new vertebral fractures 72 weeks after the start of treatment was 3.31%. Increases in the bone mineral density were observed in the lumbar spine, femoral neck, and proximal femur. The serum levels of the bone formation markers, procollagen type I N-terminal propeptide and bone-type alkaline phosphatase, increased slightly at 24 weeks and then decreased to baseline levels. At 24 and 72 weeks, the bone resorption markers, serum cross-linked N-terminal telopeptide of type I collagen and urinary cross-linked N-terminal telopeptide of type I collagen, were the same as or slightly lower than at baseline. Visual analogue scale scores for low back pain also decreased.CONCLUSIONS:
The present results showed that once-weekly teriparatide may also be useful for osteoporosis patients with a high risk of fracture.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Osteogenesis
/
Osteoporosis
/
Product Labeling
/
Spine
/
Vomiting
/
Bone Resorption
/
Biomarkers
/
Bone Density
/
Incidence
/
Low Back Pain
Type of study:
Etiology study
/
Incidence study
/
Observational study
/
Prognostic study
Limits:
Female
/
Humans
Language:
English
Journal:
Osteoporosis and Sarcopenia
Year:
2019
Type:
Article
Similar
MEDLINE
...
LILACS
LIS